Phibro Animal Health Corp (PAHC) Stock Analysis and Metrics

Phibro Animal Health

NASDAQ: PAHC

$34.06 ▲ +0.02 (+0.06%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.38 Bn

P/E14.49

P/S0.92

Div. Yield0.01

ROIC (Qtr)0.02

Total Debt (Qtr)620.52 Mn

Revenue Growth (1y) (Qtr)10.27

Add ratio to table…

About

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. It develops manufactures and markets products for food and companion animals including poultry swine beef and dairy cattle aquaculture and dogs and also produces specialty ingredients for personal care industrial chemical and chemical catalyst industries.

The company generates revenue by selling approximately eight hundred product lines in about ninety countries to roughly four thousand five hundred customers. Its Animal Health segment sells antibacterials anticoccidials nutritional specialty products vaccines and vaccine adjuvants directly to integrated poultry swine and cattle producers or through animal feed manufacturers wholesalers distributors and veterinarians. The Mineral Nutrition segment sells trace mineral formulations to fortify animal diets primarily to feed companies distributors and integrated livestock producers. The Performance Products segment sells specialty ingredients for personal care industrial chemical and chemical catalyst industries predominantly in the United States.

The company operates through the following segments: Animal Health Mineral Nutrition and Performance Products.

• Animal Health develops manufactures and markets about three hundred forty product lines including antibacterials anticoccidials nutritional specialty products vaccines and vaccine adjuvants and also provides antibacterials and processing aids used in the ethanol fermentation industry serving poultry swine beef and dairy cattle aquaculture and companion animals.

• Mineral Nutrition manufactures and markets approximately three hundred eighty formulations and concentrations of trace minerals such as zinc manganese copper iron and other compounds focusing on customers in North America to fortify animal diets and maintain optimal trace element balance including GemStone chelated organic trace minerals and the Vistore portfolio.

• Performance Products manufactures and markets specialty ingredients for use in the personal care industrial chemical and chemical catalyst industries operating through PhibroChem Ferro Metal and Chemical Corporation Limited and Phibro Tech predominantly in the United States.

Phibro Animal Health Corporation holds a leading position in the global animal health market as a top provider of medicated feed additives and nutritional specialty products with its medicated feed additive sales ranked among the three largest in the industry. The company benefits from strong brand name recognition a broad and complementary product portfolio an established direct presence in about ninety countries and an experienced sales force and technical support team that enables cross selling and deep customer relationships.

The company serves approximately four thousand five hundred customers including livestock producers such as poultry swine beef and dairy cattle farmers aquaculture producers veterinarians animal feed manufacturers wholesalers distributors and customers in the personal care industrial chemical and chemical catalyst industries.

Investment Thesis

▲ Bull case

Phibro Animal Health Corporation is positioned to capture significant long-term growth from its newly launched sustainable solutions platform, Verratain, which addresses an unmet need in the animal agriculture industry for scalable, credible Scope 3 emissions reduction tools. Management emphasized that the sustainability market based on Fortune 500 Scope 3 pledges represents tens to hundreds of billions of dollars, and while not all of that is addressable, Verratain’s design allows it to integrate into existing feed systems without requiring operational overhauls—making adoption far more feasible than competing solutions that demand major changes in farming practices. The product works across species, unlike methane-specific alternatives that are largely limited to dairy, giving PAHC a broader market reach and reducing reliance on any single segment. Furthermore, the company’s history of successfully navigating regulatory transitions—such as the antimicrobial shifts in Brazil—demonstrates an ability to turn headwinds into opportunities by maintaining demand through therapeutic use or gaining share with other portfolio products. This resilience suggests that PAHC can not only weather the virginiamycin regulatory change in Brazil but emerge stronger, particularly as its Phibro Vet platform supports compliance in a prescription-based environment. The upsized revolving credit facility by $125 million, achieved through an oversubscribed process, reflects strong underlying financial health and provides flexibility to fund strategic initiatives like Verratain’s rollout or potential bolt-on acquisitions in high-growth areas such as nutritional specialties and vaccines, which showed solid demand in Q3. Finally, the planned leadership transition to Daniel Bendheim as CEO in July, with Jack Bendheim moving to Executive Chairman, signals continuity in strategy and execution, reducing uncertainty and reinforcing confidence in the company’s long-term direction amid a stabilizing dairy market and tight beef supply supporting prices.

Phibro Animal Health Corporation is positioned to capture significant long-term growth from its newly launched sustainable solutions platform, Verratain, which addresses an unmet need in the animal agriculture industry for scalable, credible Scope 3 emissions reduction tools. Management emphasized that the sustainability market based on Fortune 500 Scope 3 pledges represents tens to hundreds of billions of dollars, and while not all of that is addressable, Verratain’s design allows it to integrate into existing feed systems without requiring operational overhauls—making adoption far more feasible than competing solutions that demand major changes in farming practices. The product works across species, unlike methane-specific alternatives that are largely limited to dairy, giving PAHC a broader market reach and reducing reliance on any single segment. Furthermore, the company’s history of successfully navigating regulatory transitions—such as the antimicrobial shifts in Brazil—demonstrates an ability to turn headwinds into opportunities by maintaining demand through therapeutic use or gaining share with other portfolio products. This resilience suggests that PAHC can not only weather the virginiamycin regulatory change in Brazil but emerge stronger, particularly as its Phibro Vet platform supports compliance in a prescription-based environment. The upsized revolving credit facility by $125 million, achieved through an oversubscribed process, reflects strong underlying financial health and provides flexibility to fund strategic initiatives like Verratain’s rollout or potential bolt-on acquisitions in high-growth areas such as nutritional specialties and vaccines, which showed solid demand in Q3. Finally, the planned leadership transition to Daniel Bendheim as CEO in July, with Jack Bendheim moving to Executive Chairman, signals continuity in strategy and execution, reducing uncertainty and reinforcing confidence in the company’s long-term direction amid a stabilizing dairy market and tight beef supply supporting prices.

▼ Bear case

Phibro Animal Health Corporation faces meaningful near-term headwinds from the regulatory shift in Brazil regarding antimicrobials like virginiamycin and bacitracin, which management acknowledged will be a headwind for fiscal year 2027 despite expressing confidence that other business growth will offset it. The company disclosed that virginiamycin sales in Brazil were $26 million in fiscal year 2025 with an above-average margin profile, suggesting the potential earnings impact could be material if therapeutic approvals are delayed or if the transition to prescription-based use results in lower adoption than anticipated. While management framed the change as the “last major shoe to drop” and cited historical success in similar transitions, the Q&A revealed no concrete mitigation strategies beyond hoping for therapeutic approvals during the 180-day transition period, leaving execution risk unaddressed. Additionally, the Performance Products segment declined 17% year-over-year in Q3 due to weaker demand for personal care ingredients, and there was no discussion of whether this reflects a structural shift or temporary softness—raising concerns about diversification benefits if multiple segments face pressure simultaneously. The company’s guidance for fiscal year 2026 implies a notable sequential slowdown, with Citi’s analyst noting the implied Q4 growth appears weak, and management attributed part of this to a conservative approach due to Middle East conflict uncertainties—yet they admitted guidance includes potential downsides from that region, suggesting the conservative stance may already be baked in, limiting upside surprise potential. Furthermore, while free cash flow was positive at $13 million for the trailing twelve months, operating cash flow of $66 million was significantly offset by $53 million in capital expenditures, and management acknowledged inventory buildup ahead of tariffs and to meet demand has negatively impacted cash generation, with stabilization only expected in coming quarters—indicating near-term cash conversion could remain strained. Finally, the leadership transition, while framed positively, introduces execution risk as Daniel Bendheim assumes the CEO role in July, and any misstep during this changeover could disrupt momentum in key growth initiatives like Verratain or the Brazil antimicrobial transition, especially given the company’s reliance on its differentiated portfolio to navigate cyclicality in beef, dairy, and poultry markets.

Phibro Animal Health Corporation faces meaningful near-term headwinds from the regulatory shift in Brazil regarding antimicrobials like virginiamycin and bacitracin, which management acknowledged will be a headwind for fiscal year 2027 despite expressing confidence that other business growth will offset it. The company disclosed that virginiamycin sales in Brazil were $26 million in fiscal year 2025 with an above-average margin profile, suggesting the potential earnings impact could be material if therapeutic approvals are delayed or if the transition to prescription-based use results in lower adoption than anticipated. While management framed the change as the “last major shoe to drop” and cited historical success in similar transitions, the Q&A revealed no concrete mitigation strategies beyond hoping for therapeutic approvals during the 180-day transition period, leaving execution risk unaddressed. Additionally, the Performance Products segment declined 17% year-over-year in Q3 due to weaker demand for personal care ingredients, and there was no discussion of whether this reflects a structural shift or temporary softness—raising concerns about diversification benefits if multiple segments face pressure simultaneously. The company’s guidance for fiscal year 2026 implies a notable sequential slowdown, with Citi’s analyst noting the implied Q4 growth appears weak, and management attributed part of this to a conservative approach due to Middle East conflict uncertainties—yet they admitted guidance includes potential downsides from that region, suggesting the conservative stance may already be baked in, limiting upside surprise potential. Furthermore, while free cash flow was positive at $13 million for the trailing twelve months, operating cash flow of $66 million was significantly offset by $53 million in capital expenditures, and management acknowledged inventory buildup ahead of tariffs and to meet demand has negatively impacted cash generation, with stabilization only expected in coming quarters—indicating near-term cash conversion could remain strained. Finally, the leadership transition, while framed positively, introduces execution risk as Daniel Bendheim assumes the CEO role in July, and any misstep during this changeover could disrupt momentum in key growth initiatives like Verratain or the Brazil antimicrobial transition, especially given the company’s reliance on its differentiated portfolio to navigate cyclicality in beef, dairy, and poultry markets.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	87.22 Bn	102.28	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	39.60 Bn	23.19	2.28	16.63 Bn
3	ZTS	Zoetis Inc.	31.46 Bn	11.90	3.31	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	26.49 Bn	-10.03	0.57	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.03 Bn	17.89	7.27	-
6	UPC	Universe Pharmaceuticals INC	23.03 Bn	0.00	1.29	7.15 Bn
7	VTRS	Viatris Inc	20.90 Bn	-67.34	1.43	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.50 Bn	26.18	5.64	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password